Citations (79)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Keiji Hirai, Hiroaki Nonaka, Moeka Ueda, Junki Morino, Shohei Kaneko, Saori Minato, Yuko Mutsuyoshi, Katsunori Yanai, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara & Yoshiyuki Morishita. (2021) No Significant Changes of Glycemic Control and Renal Function in Patients with Advanced-Stage Diabetic Kidney Disease by Switching from Linagliptin to Teneligliptin. Pragmatic and Observational Research 12, pages 81-91.
Read now
Read now
Masahiro Takihata & Yasuo Terauchi. (2019) The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study. Expert Opinion on Pharmacotherapy 20:17, pages 2185-2194.
Read now
Read now
André Jacques Scheen. (2018) The safety of gliptins : updated data in 2018. Expert Opinion on Drug Safety 17:4, pages 387-405.
Read now
Read now
André J. Scheen. (2017) Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert Review of Clinical Pharmacology 10:12, pages 1303-1316.
Read now
Read now
André J. Scheen. (2017) Pharmacological management of type 2 diabetes: what’s new in 2017?. Expert Review of Clinical Pharmacology 10:12, pages 1383-1394.
Read now
Read now
Sayf A Yassin & Vanita R Aroda. (2017) Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Design, Development and Therapy 11, pages 923-937.
Read now
Read now
André J. Scheen. (2017) Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 13:5, pages 583-592.
Read now
Read now
André J. Scheen. (2017) Dulaglutide for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy 17:4, pages 485-496.
Read now
Read now
André J. Scheen. (2017) Pharmacotherapy of ‘treatment resistant’ type 2 diabetes. Expert Opinion on Pharmacotherapy 18:5, pages 503-515.
Read now
Read now
André J. Scheen. (2016) DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opinion on Drug Metabolism & Toxicology 12:12, pages 1407-1417.
Read now
Read now
André J. Scheen. (2016) Investigational insulin secretagogues for type 2 diabetes. Expert Opinion on Investigational Drugs 25:4, pages 405-422.
Read now
Read now
André J. Scheen. (2016) Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Review of Clinical Pharmacology 9:3, pages 385-399.
Read now
Read now
Gina Ryan. (2015) Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors. Postgraduate Medicine 127:8, pages 842-854.
Read now
Read now
André J Scheen. (2015) Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 1005-1020.
Read now
Read now
Takashi Kadowaki, Fuyuhiko Marubayashi, Shoko Yokota, Makoto Katoh & Hiroaki Iijima. (2015) Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies. Expert Opinion on Pharmacotherapy 16:7, pages 971-981.
Read now
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
Articles from other publishers (63)
Emi Kawakita, Fan Yang, Sen Shi, Yuta Takagaki, Daisuke Koya & Keizo Kanasaki. (2023) Inhibition of Dipeptidyl Peptidase-4 Activates Autophagy to Promote Survival of Breast Cancer Cells via the mTOR/HIF-1α Pathway. Cancers 15:18, pages 4529.
Crossref
Crossref
Antonella Ilenia Alfano, Andrea Sorato, Alessia Ciogli, Heiko Lange & Margherita Brindisi. (2023) Enantioselective catalytic Strecker reaction on cyclic (Z)-aldimines in flow: reaction optimization and sustainability aspects. Journal of Flow Chemistry.
Crossref
Crossref
Md Saddam Hossain, Sadia Jahan, Sad Al Rezwan Rahman, Mashiur Rahman, Diponkor Kumar, Susmita Paul & Joy Chandra Rajbangshi. (2023) Design expert software assisted development and evaluation of empagliflozin and sitagliptin combination tablet with improved in-vivo anti-diabetic activities. Heliyon 9:3, pages e14259.
Crossref
Crossref
Donald J. AbrahamAnn E. Weber & Nancy A. Thornberry. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
48
.
Felix F. Lillich, John D. Imig & Ewgenij Proschak. (2021) Multi-Target Approaches in Metabolic Syndrome. Frontiers in Pharmacology 11.
Crossref
Crossref
Charalampos I. Liakos, Dimitrios P. Papadopoulos, Elias A. Sanidas, Maria I. Markou, Erifili E. Hatziagelaki, Charalampos A. Grassos, Maria L. Velliou & John D. Barbetseas. (2020) Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors). American Journal of Cardiovascular Drugs 21:2, pages 123-137.
Crossref
Crossref
Qin Zhang, Ming Yang, Ying Xiao, Yachun Han, Shikun Yang & Lin Sun. (2021) Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy. Current Medicinal Chemistry 28:5, pages 1003-1024.
Crossref
Crossref
Alexandros Sachinidis, Dragana Nikolic, Anca Pantea Stoian, Nikolaos Papanas, Omer Tarar, Ali A. Rizvi & Manfredi Rizzo. (2020) Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism 111, pages 154343.
Crossref
Crossref
Sounak Ghosh, Dongling Luo, Wanbing He, Jie Chen, Xiaoyan Su & Hui Huang. (2020) Diabetes and calcification: The potential role of anti-diabetic drugs on vascular calcification regression. Pharmacological Research 158, pages 104861.
Crossref
Crossref
Zhenhua Liu, Lanting Xu, Meimei Xing, Xiaojie Xu, Jinfeng Wei, Jinmei Wang & Wenyi Kang. (2020) Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes. Biomedicine & Pharmacotherapy 125, pages 109952.
Crossref
Crossref
Minyoung Lee, Jiyu Sun, Minkyung Han, Yongin Cho, Ji-Yeon Lee, Chung Mo Nam & Eun Seok Kang. (2019) Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors. Diabetes Care 42:11, pages 2057-2064.
Crossref
Crossref
Ravi Kant, Ramesh Babu BodlaRubina Bhutani & Garima Kapoor. (2019) Enantioselective Box Behenken Optimized HPLC-DAD Method for the Simultaneous Estimation of Alogliptin Enantiomorphs in Pharmaceutical For mulations and their Pharmacokinetic Study in Rat Plasma. Advanced Pharmaceutical Bulletin 9:1, pages 147-158.
Crossref
Crossref
Grazyna Lietzau, William Davidsson, Claes-Göran Östenson, Fausto Chiazza, David Nathanson, Hiranya Pintana, Josefin Skogsberg, Thomas Klein, Thomas Nyström, Vladimer Darsalia & Cesare Patrone. (2018) Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin. Acta Neuropathologica Communications 6:1.
Crossref
Crossref
A.J. Scheen. (2018) Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies. Diabetes & Metabolism 44:5, pages 386-392.
Crossref
Crossref
Y.K. Cho, Y.M. Kang, S.E. Lee, J. Lee, J.-Y. Park, W.J. Lee, Y.-J. Kim & C.H. Jung. (2018) Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis. Diabetes & Metabolism 44:5, pages 393-401.
Crossref
Crossref
Xia Wang, Peilin Zheng, Gan Huang, Lin Yang & Zhiguang Zhou. (2018) Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes. Clinical and Experimental Medicine 18:4, pages 473-480.
Crossref
Crossref
Tomoaki Koshizawa, Toshiharu Morimoto, Gen Watanabe, Tomoaki Fukuda, Nao Yamasaki, Sumihiko Hagita, Yoshikazu Sawada, Ayumu Okuda, Kimiyuki Shibuya & Tadaaki Ohgiya. (2018) Discovery of novel spiro[chromane-2,4′-piperidine] derivatives as potent and orally bioavailable G-protein-coupled receptor 119 agonists. Bioorganic & Medicinal Chemistry Letters 28:19, pages 3236-3241.
Crossref
Crossref
Joelle de Melo Turnes, Taysa Bervian Bassani, Leonardo C Souza & Maria A B F Vital. (2018) Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats. Journal of Pharmacy and Pharmacology 70:8, pages 1059-1068.
Crossref
Crossref
André J. Scheen. (2018) Cardiovascular Effects of New Oral Glucose-Lowering Agents. Circulation Research 122:10, pages 1439-1459.
Crossref
Crossref
Ning Li, Li-Jun Wang, Bo Jiang, Xiang-qian Li, Chuan-long Guo, Shu-ju Guo & Da-Yong Shi. (2018) Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. European Journal of Medicinal Chemistry 151, pages 145-157.
Crossref
Crossref
A.J. Scheen & P. Delanaye. (2018) Renal outcomes with dipeptidyl peptidase-4 inhibitors. Diabetes & Metabolism 44:2, pages 101-111.
Crossref
Crossref
Vladimir V. Kouznetsov & Carlos E. Puerto Galvis. (2018) Strecker reaction and α-amino nitriles: Recent advances in their chemistry, synthesis, and biological properties. Tetrahedron 74:8, pages 773-810.
Crossref
Crossref
Taro Uchida, Masaki Wakasugi, Takahiro Kitamura, Tomomi Yamamoto, Mitsutoshi Asakura, Ryoichi Fujiwara, Tomoo Itoh, Hideaki Fujii & Shuichi Hirono. (2018) Exploration of DPP-IV inhibitors with a novel scaffold by multistep in silico screening. Journal of Molecular Graphics and Modelling 79, pages 254-263.
Crossref
Crossref
Torsten Steinmetzer & Kornelia Hardes. 2018. Activation of Viruses by Host Proteases. Activation of Viruses by Host Proteases
279
325
.
P. Men, N. He, C. Song & S. Zhai. (2017) Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis. Diabetes & Metabolism 43:6, pages 493-500.
Crossref
Crossref
Xiaoyan Deng, Li Han, Jinpei Zhou, Huibin Zhang & Qing Li. (2017) Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors. Bioorganic Chemistry 75, pages 357-367.
Crossref
Crossref
Hironobu Maezaki, Michiko Tawada, Tohru Yamashita, Yoshihiro Banno, Yasufumi Miyamoto, Yoshio Yamamoto, Koji Ikedo, Takuo Kosaka, Shigetoshi Tsubotani, Akiyoshi Tani, Tomoko Asakawa, Nobuhiro Suzuki & Satoru Oi. (2017) Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554. Bioorganic & Medicinal Chemistry Letters 27:15, pages 3565-3571.
Crossref
Crossref
Ildiko Lingvay. (2017) Sodium Glucose Cotransporter 2 and Dipeptidyl Peptidase-4 Inhibition: Promise of a Dynamic Duo. Endocrine Practice 23:7, pages 831-840.
Crossref
Crossref
Sara T. Hjuler, Sofie Gydesen, Kim V. Andreassen, Morten A. Karsdal & Kim Henriksen. (2017) The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042 Works as Adjunct to Metformin on Fasting Hyperglycemia and HbA1c in a Rat Model of Type 2 Diabetes. Journal of Pharmacology and Experimental Therapeutics 362:1, pages 24-30.
Crossref
Crossref
André J. Scheen. (2016) Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. Clinical Pharmacokinetics 56:7, pages 703-718.
Crossref
Crossref
André J. Scheen. (2017) Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. Diabetes Research and Clinical Practice 127, pages 224-237.
Crossref
Crossref
Chang Xia, Aditya Goud, Jason D’Souza, CHanukya Dahagam, Xiaoquan Rao, Sanjay Rajagopalan & Jixin Zhong. (2017) DPP4 inhibitors and cardiovascular outcomes: safety on heart failure. Heart Failure Reviews 22:3, pages 299-304.
Crossref
Crossref
Fabrice Bonnet & André Scheen. (2017) Understanding and overcoming metformin gastrointestinal intolerance. Diabetes, Obesity and Metabolism 19:4, pages 473-481.
Crossref
Crossref
Wen Xu, Yiming Mu, Jiajun Zhao, Dalong Zhu, Qiuhe Ji, Zhiguang Zhou, Bin Yao, Anhua Mao, Samuel S. Engel, Bin Zhao, Yan Bi, Longyi Zeng, Xingwu Ran, Juming Lu, Linong Ji, Wenying Yang, Weiping Jia & Jianping Weng. (2017) Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. Science China Life Sciences 60:3, pages 225-238.
Crossref
Crossref
Shereen Mowaka, Ehab F. Elkady, Mohamed M. Elmazar & Bassam M. Ayoub. (2017) Enhanced LC-MS/MS determination of alogliptin and metformin in plasma: Application to a pharmacokinetic study. Microchemical Journal 130, pages 360-365.
Crossref
Crossref
Michel Hermans, Luc Van Gaal, Ingrid R?zette, Evis Daci, Karen MacDonald, Kris Denhaerynck, Stefaan Vancayzeele, Lut De Meester, Andreas Clemens, Brian Yee & Ivo Abraham. (2016) Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study). Primary Care Diabetes 10:6, pages 425-433.
Crossref
Crossref
Pablo Yang, Verónica Ojeda Heredia, Dante M. Beltramo & Néstor W. Soria. (2016) Pharmacogenetics and personalized treatment of type 2 diabetes mellitus. International Journal of Diabetes in Developing Countries 36:4, pages 508-518.
Crossref
Crossref
Rajesh Krishna, Carol Addy, Daniel Tatosian, Xiaoli S. Glasgow, Isaias Noel Gendrano III, Martine Robberechts, Wouter Haazen, J.N. Hoon, Marleen Depré, Ashley Martucci, Joanna Z. Peng, Amy O. Johnson‐Levonas, John A. Wagner & S. Aubrey Stoch. (2016) Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects. The Journal of Clinical Pharmacology 56:12, pages 1528-1537.
Crossref
Crossref
R.C. Bonadonna, C. Borghi, A. Consoli & M. Volpe. (2016) Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. Nutrition, Metabolism and Cardiovascular Diseases 26:9, pages 759-766.
Crossref
Crossref
Merlin C. Thomas, Päivi M. Paldánius, Rajeev Ayyagari, Siew Hwa Ong & Per-Henrik Groop. (2016) Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment. Diabetes Therapy 7:3, pages 439-454.
Crossref
Crossref
Daniel A. Tatosian, Nadia Cardillo Marricco, Xiaoli Shirley Glasgow, Bruce DeGroot, Katherine Dunnington, Laura George, Isaias Noel Gendrano, Amy O. Johnson-Levonas, Dennis Swearingen & Eunkyung Kauh. (2016) A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval. Clinical Pharmacology in Drug Development 5:5, pages 383-392.
Crossref
Crossref
Gisela Schnapp, Thomas Klein, Yvette Hoevels, Remko A. Bakker & Herbert Nar. (2016) Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure. Journal of Medicinal Chemistry 59:16, pages 7466-7477.
Crossref
Crossref
Jonathan M. Hazlehurst, Conor Woods, Thomas Marjot, Jeremy F. Cobbold & Jeremy W. Tomlinson. (2016) Non-alcoholic fatty liver disease and diabetes. Metabolism 65:8, pages 1096-1108.
Crossref
Crossref
André J. Scheen. (2016) Precision medicine: The future in diabetes care?. Diabetes Research and Clinical Practice 117, pages 12-21.
Crossref
Crossref
Dongyang Liu, Xifeng Ma, Yang Liu, Huimin Zhou, Chongtie Shi, Frank Wu, Ji Jiang & Pei Hu. (2016) Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods. European Journal of Pharmaceutical Sciences 89, pages 73-82.
Crossref
Crossref
V. Darsalia, M. Larsson, G. Lietzau, D. Nathanson, T. Nyström, T. Klein & C. Patrone. (2016) Gliptin‐mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon‐like peptide‐1 receptor. Diabetes, Obesity and Metabolism 18:5, pages 537-541.
Crossref
Crossref
Jay J. Salazar, William J. Ennis & Timothy J. Koh. (2016) Diabetes medications: Impact on inflammation and wound healing. Journal of Diabetes and its Complications 30:4, pages 746-752.
Crossref
Crossref
Bo Ahrén & James E. Foley. (2016) Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia 59:5, pages 907-917.
Crossref
Crossref
Alice B Nongonierma & Richard J FitzGerald. (2016) Prospects for the management of type 2 diabetes using food protein-derived peptides with dipeptidyl peptidase IV (DPP-IV) inhibitory activity. Current Opinion in Food Science 8, pages 19-24.
Crossref
Crossref
Carol Addy, Daniel Tatosian, Xiaoli S. Glasgow, Isaias N. GendranoIIIIII, Eunkyung Kauh, Ashley Martucci, Amy O. Johnson-Levonas, Diana Selverian, Catherine Z. Matthews, Marie Gutierrez, John A. Wagner & S. Aubrey Stoch. (2016) Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus. Clinical Therapeutics 38:3, pages 516-530.
Crossref
Crossref
William B. WhiteWilliam L. Baker. (2016) Cardiovascular Effects of Incretin-Based Therapies. Annual Review of Medicine 67:1, pages 245-260.
Crossref
Crossref
Qing Li, Li Han, Bin Zhang, Jinpei Zhou & Huibin Zhang. (2016) Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors. Organic & Biomolecular Chemistry 14:40, pages 9598-9611.
Crossref
Crossref
Brian A. BaldoBrian A. Baldo. 2016. Safety of Biologics Therapy. Safety of Biologics Therapy
309
400
.
Sander Kooijman, José K. van den Heuvel & Patrick C.N. Rensen. (2015) Neuronal Control of Brown Fat Activity. Trends in Endocrinology & Metabolism 26:11, pages 657-668.
Crossref
Crossref
Qing Li, Muxing Zhou, Li Han, Qing Cao, Xinning Wang, LeiLei Zhao, Jinpei Zhou & Huibin Zhang. (2015) Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors. Chemical Biology & Drug Design 86:4, pages 849-856.
Crossref
Crossref
P. J. Lef?bvre, N. Paquot & A. J. Scheen. (2015) Inhibiting or antagonizing glucagon: making progress in diabetes care. Diabetes, Obesity and Metabolism 17:8, pages 720-725.
Crossref
Crossref
A.J. Scheen, N. Esser & N. Paquot. (2015) Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. Diabetes & Metabolism 41:3, pages 183-194.
Crossref
Crossref
André J. Scheen. (2015) Author’s Reply to De Ponti et al.: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”. Clinical Pharmacokinetics 54:4, pages 449-451.
Crossref
Crossref
André J Scheen. (2015) Once-weekly DPP-4 inhibitors: do they meet an unmet need?. The Lancet Diabetes & Endocrinology 3:3, pages 162-164.
Crossref
Crossref
A.-J. Scheen. (2015) Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique. Médecine des Maladies Métaboliques 9:2, pages 186-197.
Crossref
Crossref
Thiago Salles, Leonardo dos Santos, Valério Barauna & Adriana Girardi. (2015) Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure. International Journal of Molecular Sciences 16:2, pages 4226-4249.
Crossref
Crossref
Jang Won SonSungrae Kim. (2015) Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies. Diabetes & Metabolism Journal 39:5, pages 373.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes. Clinical Pharmacokinetics 54:1, pages 1-21.
Crossref
Crossref